Search the Newsreel

Tyranna Resources (ASX:TYX): Why Is Its Mining Reset in Focus?

Tyranna Resources (ASX:TYX): What Is Driving Its Mining Story?

Why Is Tyranna Resources (ASX:TYX) Back in Market Focus?

Insiders In Tyranna Resources Left Out From 33% Price Rise After Disposing Stock

Avoiding Lag: Real-Time Signals in (TYRA) Movement

The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.

Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside

Analysts have slightly cut the average 12-month price target for Tyra Biosciences, Inc. (TYRA) stock from $51.09 to $50.82, with individual forecasts ranging from $39 to $59. This updated target suggests a potential upside of approximately 94% based on the recent closing price. The …

Tyranna Resources Issues Over 26 Million Unquoted Options

Tyranna Resources Seeks ASX Quotation for 17.4 Million New Shares

Tyranna Shareholders Back Angolan Acquisition and Strategic Asset Shift

HC Wainwright Brokers Lower Earnings Estimates for TYRA

Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42

Jefferies has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and increased its price target to $42. This indicates a positive outlook from the firm regarding the company's future performance.

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from fifteen research firms, with an average 12-month price target of $46.90. Despite this optimistic outlook, the company's shares recently declined by 21% to $25.71, trading below its 50-day and 200-day moving averages. …

Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday

Tyra Biosciences (TYRA) Reports Q2 Results, Is The Pipeline Potential Already Priced In?

Tyra Biosciences (TYRA) reported Q2 2026 results, showing a wider net loss but also experiencing significant share price momentum over the past year. The article questions whether the market has already fully priced in the potential of its development pipeline, given its 1-year total …

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings

Tyra Biosciences (NASDAQ:TYRA) shares gapped down following a disappointing earnings announcement, missing the consensus EPS estimate. Despite this, analyst sentiment remains "Moderate Buy" with an average price target of $47.00. Institutional ownership is high at 84.14%, with several major investors increasing their stakes.

TYRA Shares Drop Amid Market Volatility; Price-to-Sales Highligh

Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028

Tyra Biosciences reported a Q2 2026 net loss of $45.6 million, ending the quarter with $353.9 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2028. The company is advancing its dabogratinib programs, with key clinical readouts …

BlackRock, Inc. Expands Tyra Biosciences (TYRA) Stake with Strat

Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary

Tyra Biosciences reported a net loss of $45.6 million, or $(0.69) per diluted share, for the second quarter of 2026, which is an increase from the $28.1 million net loss in the prior year. The company maintains a strong liquidity position with $353.9 million …

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences announced its second-quarter 2026 financial results, highlighted by initial Phase 2 data from SURF302 for bladder cancer expected in September 2026 and an expanded fifth dose level for the BEACH301 study in achondroplasia. The company reported $353.9 million in cash, cash equivalents, …

Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA

Arkadios Wealth Advisors has made a new investment of $1.82 million in Tyra Biosciences, Inc., acquiring 47,567 shares. This comes as institutional investors and hedge funds collectively own a significant 84.14% of the company. Despite Tyra Biosciences missing its Q1 earnings estimates, analysts maintain …

Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP significantly increased its stake in Tyra Biosciences (TYRA) by 149.6% in Q1 2026, holding 198,585 shares worth $7.6 million. This move is part of a broader trend of institutional investment, with several other firms also boosting their positions. Analysts …

Discipline and Rules-Based Execution in TYRA Response

This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models to provide trading strategies. It highlights positive near-term sentiment within a long-term strength context, noting that support is being tested. The analysis identifies an exceptional risk-reward setup and offers distinct position, momentum breakout, …

BlackRock (TYRA holder) reports 2.98M TYRA Biosciences shares, a 5% passive stake

BlackRock, Inc. has reported a 5% passive ownership stake in TYRA Biosciences, Inc., beneficially owning 2,976,228 shares of common stock. BlackRock holds sole voting power over 2,924,904 shares and sole dispositive power over all its beneficially owned shares. The filing indicates that no single …

Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP

Eversept Partners LP drastically reduced its stake in Tyra Biosciences (NASDAQ:TYRA) by 90.3% in the first quarter, selling over 251,000 shares. Despite this, institutional investors still collectively own a significant 84.14% of the company's stock, and Wall Street analysts maintain a "Moderate Buy" consensus …

Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Tyra Biosciences Inc (TYRA), covering business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant financial data, leading to an empty report. The article essentially states that …

Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Tyra Biosciences Inc (TYRA) stock, evaluating various indicators and moving averages. It summarizes the signals from MACD, RSI, KDJ, and others, indicating a neutral stance overall, with specific buy and sell signals from different metrics. The analysis …

Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Tyra Biosciences Inc (TYRA) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The financial snapshot …

Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Tyra Biosciences Inc (TYRA), focusing on its P/E and P/B ratios. However, it indicates that relevant data for these metrics have not yet been disclosed by the company. The page also presents current stock performance and market …

Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing major shareholders like RA Capital Management, LP, Nextech Invest, Ltd., and Alta Partners with their respective proportions. It also breaks down shareholder types, institutional holdings over various reporting periods, and related ETF …

Tyra Biosciences Inc (TYRA) Cash Flow

This article provides a detailed historical cash flow statement for Tyra Biosciences Inc (TYRA), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, operating cash flow, capital expenditures, and free cash flow, along with …